AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01864590 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Double Sylo Bag - Mesh Protocol
Description: double sylo bag, one underneath the fascia and the other sutured to the skin, at the initial operation.~At subsequent surgeries once the abdomen is clean the investigators leave the same subfascial sylo bag and use a prolene mesh attached to the fascia. This mesh is resutured every day until the abdominal fascia is approximated enough to permit closure
Study NCT01141985 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: LenSx Laser modified disposable contact lens
Description: Modified Disposable Contact Lens Patient Interface: Like the current disposable contact lens, a single unit is used for each procedure only once, and is then discarded. It is similarly mounted onto the distal end of the system's focusing objective and serves as a sterile barrier between the patient and the laser. In place of a separate suction ring that is used in the current contact lens, the modified contact lens has an integrated suction ring and curved applanation surface. These features result in significantly lower elevation of intraocular pressure and significantly easier application by the surgeon in preliminary testing. Identical to the current contact lens, the suction ring is applied around the patient's limbus and mild suction is applied to stabilize the eye.
Study NCT03927963 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine 0.7 ug/kg/h with sevoflurane 0.5 MAC and remifentanil infusion are used throughout anesthesia period
Study NCT03927963 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: Effect site concentration of propofol 1.5 ng/ml with sevoflurane 0.5 MAC and remifentanil infusion are used throughout anesthesia period
Study NCT00801528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine, Diclofenac, Water for injection
Description: Ropivacaine 0.2 %, or diclofenac (300 mg/240 ml water for injection) or water for injection will be administered as a constant instillation rate set of 10 mL/hr for the subsequent 18 postoperative hours.
Study NCT00801528 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine, Diclofenac, Water for injection
Description: Ropivacaine 0.2 %, or diclofenac (300 mg/240 ml water for injection) or water for injection will be administered as a constant instillation rate set of 10 mL/hr for the subsequent 18 postoperative hours.
Study NCT00499603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 500 mg/m\^2 by vein on day 1 every 3 weeks (+/- 7 days) for 4 cycles.
Study NCT00499603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: 30 mg by mouth weekly on Days 1, 8, \& 15 for 12 cycles.
Study NCT05660694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone
Description: Comparison of Triamcinolone with Pentoxifylline and Vitamin- E Efficacy
Study NCT05660694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline with Vitamin E
Description: Comparison of Triamcinolone with Pentoxifylline and Vitamin- E Efficacy
Study NCT04720521 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: OE+white light
Description: Firstly use white light to observe from esophagus to duodenum and then switch OE mode to observe from antrum to esophagus
Study NCT01985750 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: d-cycloserine
Description: 250mg d-cycloserine or identical placebo given immediately to the first 4 sessions of a 6-week course pulmonary rehabilitation.
Study NCT01985750 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Other Names:~comparison of d-cycloserine or placebo on enhancing the beneficial effects of pulmonary rehabilitation on breathlessness perception~250mg d-cycloserine or identical placebo given immediately to the first 4 sessions of a 6-week course pulmonary rehabilitation
Study NCT00526591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Patients will receive arm-specific dosage of Everolimus daily continuously for 8 week
Study NCT00526591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Patients will receive arm-specific dosage of Everolimus daily continuously for 8 week
Study NCT00526591 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional surgery
Description: Radical prostatectomy with bilateral pelvic lymphadenectomy will be performed within 10 days of the completion of week 8 on RAD-001 (Everolimus).
Study NCT00526591 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Radical prostatectomy with bilateral pelvic lymphadenectomy will be performed within 10 days of the completion of week 8 on RAD-001 (Everolimus).
Study NCT01062152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezatiostat Hydrochloride
Description: Starting dose 2000 mg orally in divided doses twice daily (1000 mg in AM \& 1000 mg in PM) x 21 days with one week off therapy in a 4-week cycle.
Study NCT01062152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide (Revlimid®)
Description: 10 mg orally per day in one AM dose x 21 days with one week off therapy in a 4-week cycle.
Study NCT04947241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor+ Gemcitabine + Cisplatin
Description: Before surgery, patients will receive therapy as follows:~PD-1 inhibitor: 240mg (day1) , intravenous, Q3W, 2cycles; cisplatin: 80 mg/m2(day1), intravenous , intravenous, Q3W, 2cycles Gemcitabine: 1000mg/m2(day1and day8), intravenous, Q3W, 2cycles
Study NCT01057186 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Alfacalcidol; phosphate.
Description: Individual dosage form and dosage depending on phenotype and underlying cause.
Study NCT01057186 — intervention group
Intervention type: DRUG
Intervention: Sevelamer
Description: Pills. Individual dosage depending on clinical symptoms/phenotype.
Study NCT01441804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa2a
Description: patients receive a dose of 180 µg of PEGASYS once a week for 24 weeks
Study NCT01441804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 24 weeks
Study NCT01441804 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa2a
Description: patients receive a dose of 180 µg of PEGASYS once a week for 48 weeks
Study NCT01441804 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 48 weeks
Study NCT00116220 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flutamide (Eulexin) and Lupron or Zoladex
Description: Androgen suppression therapy
Study NCT00116220 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External Beam Radiotherapy
Description: Once a day, 4-5 days per week for approximately 2 months
Study NCT01731366 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole grain
Description: Whole grain diet: Participants consume more than 75g of whole grain per day (corresponds to the whole grain intake of the 90th percentile of the population)
Study NCT01731366 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Refined grain
Description: Refined grain diet: Participants consume less than 10 g of whole grain per day (corresponds to the whole grain intake below the 10th percentile of the population)
Study NCT04273893 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT with additional treatment planning dose optimization
Description: Lung SBRT 50-60Gy in 5 fractions with standard of care planning and additional treatment planning dose optimization criteria to minimize decrease in lymphocyte count beyond dosimetric criteria from RTOG 0915/0813 SBRT trials.
Study NCT04273893 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SBRT with standard of care planning only
Description: Lung SBRT 50-60Gy in 5 fractions with standard of care planning (no additional dose optimization beyond SOC)
Study NCT04273893 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood Draws
Description: CBC w/ Diff and additional blood analysis for all participants in both groups. Blood draws will prior to treatment, end of treatment, 4 weeks after treatment, and 6 months after treatment.
Study NCT04273893 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Blood Draws
Description: CBC w/ Diff and additional blood analysis for all participants in both groups. Blood draws will prior to treatment, end of treatment, 4 weeks after treatment, and 6 months after treatment.
Study NCT02588261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naquotinib mesilate
Description: Participants received ASP8273 300 mg orally once daily on an empty stomach (no food for at least 2 hours before and 1 hour after taking drug) at approximately the same time every day.
Study NCT02588261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: Participants received erlotinib 150 mg orally once daily on an empty stomach (no food for at least 2 hours before and 1 hour after taking drug) at approximately the same time every day. At the beginning of the trial, prior to site initiation and shipment of study drug supplies, each investigator selected either erlotinib or gefitinib to be utilized for all participants randomized to the comparator arm at their site.
Study NCT02588261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib
Description: Participants received gefitinib 250 mg was taken orally once daily with water, with or without food, at approximately the same time every day. At the beginning of the trial, prior to site initiation and shipment of study drug supplies, each investigator selected either erlotinib or gefitinib to be utilized for all participants randomized to the comparator arm at their site.
Study NCT01898429 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SCC DBS
Description: Deep Brain Stimulator
Study NCT03653143 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: JASPER
Description: JASPER is a therapist and parent-mediated intervention that (1) targets the foundations of social communication, (2) uses naturalistic behavioral strategies to increase the rate and complexity of social communication and (3) includes parents as implementers of the intervention to promote generalization across settings and to ensure maintenance. This intervention is individualized and centered around two key developmental domains critical for social communication function: joint engagement and joint attention.
Study NCT01035619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxidectin
Description: Single Dose Moxidectin 4 mg
Study NCT03325842 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ASKp
Description: 30 items questionnaire
Study NCT02287467 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravenous hyperimmune immunoglobulin (IVIG)
Description: Administered intravenously (IV) at a dose of 0.25 g/kg (up to a maximum of 24.75 g, corresponding to approximately 100 kg actual body weight)
Study NCT02287467 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for IVIG
Description: Administered IV as 500 mL of normal saline
Study NCT03020706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate, Injectable
Description: magnesium sulphate intravenous administration during general anesthesia
Study NCT00255788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: everolimus
Study NCT03106636 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: KEEP-P
Description: The KEEP-P program is a low-cost, manualized, group-based intervention for caregivers of preschool aged children. This trial is evaluating 2 versions of the intervention. KEEP-P is a basic version that employs a curriculum of 12 weekly psychoeducational caregiver support groups Across four waves of data collection (baseline, post-intervention, and 12 and 18 months post-baseline), we will examine the extent to which this intervention condition shows improved parenting, reduced rates of disrupted placements, and improved child outcomes.
Study NCT03106636 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KEEP-P+
Description: The KEEP-P program is a low-cost, manualized, group-based intervention for caregivers of preschool aged children. This trial is evaluating 2 versions of the intervention. KEEP-P+ is an augmented version that consists of the caregiver support groups with extended curriculum including information about recent findings in early brain development and the elements of the Filming Interactions to Nurture Development video coaching program. Across four waves of data collection (baseline, post-intervention, and 12 and 18 months post-baseline), we will examine the extent to which this intervention condition show improved parenting, reduced rates of disrupted placements, and improved child outcomes.
Study NCT04233541 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fall assessment
Description: Through a comprehensive geriatric assessment carried out by our geriatrician led multidisciplinary team we gather information about fall recalls consistent with the definition of landing on the floor or ground.
Study NCT03630757 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment
Description: In the study group, a total of 15 sessions of a manual therapy program including myofascial release and mobilization techniques were applied for 60-minute session for 3 weeks(5/wk).
Study NCT03630757 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment
Description: In the study group, a total of 15 sessions of a manual therapy program including myofascial release and mobilization techniques were applied for 60-minute session for 3 weeks(5/wk).
Study NCT02529176 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Best-practice alert
Description: The best-practice alert notifies physicians that their patient's telemetry monitoring duration has exceeded national guidelines and gives the physician the option to: discontinue monitoring if they feel it is clinically appropriate, dismiss the alert, or re-alert in four hours.
Study NCT00958971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKI258
Description: All participants received a singly daily oral dose of 500 mg dovitinib on a 5 days on/2 days off schedule in 28 cycles.
Study NCT01103934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: 4000 IU once daily
Study NCT01103934 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken once daily
Study NCT01103934 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluticasone Propionate
Description: 200 mcg daily, intranasal
Study NCT01401517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium nitrite
Description: 0, 40 or 80 mg twice each day for 10 weeks followed by a 1 week escalation of 2 times the dose.
Study NCT01401517 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sodium nitrite
Description: 0, 40 or 80 mg twice each day for 10 weeks followed by a 1 week escalation of 2 times the dose.
Study NCT01766180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fruitflow-II
Description: 150 mg/day for 3 months, orally
Study NCT01766180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: resVida
Description: 150 mg/day for 3 months, orally
Study NCT02458573 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: continuous epidural analgesia
Description: the continuous epidural analgesia group: epidural analgesia started from induction of anesthesia and continued for 48 h.
Study NCT02458573 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: continuous intravenous analgesia
Description: the continuous intravenous analgesia group: intravenous analgesia started from induction of anesthesia and continued for 48 h.
Study NCT02398604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allo-hMSCs
Description: Allogeneic Human Mesenchymal Stem Cells
Study NCT02398604 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02159976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: Pantoprazole 40mg bid
Study NCT02159976 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole
Description: Pantoprazole 40mg bid
Study NCT02159976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Amoxicillin 1000mg bid
Study NCT02159976 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Amoxicillin 1000mg bid
Study NCT01103934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate
Description: 200 mcg daily, intranasal
Study NCT02159976 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: Clarithromycin 500mg bid
Study NCT02159976 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Metronidazole 500mg tid
Study NCT02159976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracycline
Description: Tetracycline 1000mg bid
Study NCT02159976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth
Description: Bismuth 600mg bid
Study NCT06341998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus combined with chemotherapy in the treatment of recurrent/refractory yolk sac tumor in children
Description: The oral dose of sirolimus is 1mg/m2 daily (maximum 2 mg). Sirolimus whole blood trough concentration is measured 5 days after administration, with blood collected within half an hour before morning administration. Dose adjustment occurs weekly until the target range of 10-15ng/ml is achieved, followed by review every 21 days. Each cycle lasts for 21 days (every three weeks), and if treatment parameters are met as described in the study, cycle two and subsequent cycles begin on day 22. Treatment will be discontinued if there is drug-related dose-limiting toxicity or disease progression. Tumor response assessment will be repeated using AFP and LDH every one cycle and imaging examination every two cycles. Children who complete the trial may continue this regimen or undergo surgery or radiation therapy if their disease goes into remission.
Study NCT00668746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline HCl microspheres
Description: At Baseline and all interim visits, a single unit dose of 1mg minocycline HCl (with approximately 3mg PGLA) will be professionally administered subgingivally into periodontal pockets at each site exhibiting a PD ≥ 5mm.
Study NCT02717780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl and sevoflurane
Study NCT02717780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil and desflurane
Study NCT01717625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: a leukotriene D4 receptor antagonist; sodium salt is the active compound; structure in first source
Study NCT04184622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC
Study NCT02759250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARGX-110
Study NCT02362750 — intervention group
Intervention type: OTHER
Intervention: Organizational Interview
Description: Survivorship program leaders will participate in a phone-based organizational interview regarding the organization of the clinical survivorship care program.
Study NCT02362750 — intervention group
Intervention type: OTHER
Intervention: Organizational Survey
Description: Survivorship program leaders will participate in a brief web-based organizational survey regarding the organization of the clinical survivorship care program.
Study NCT02362750 — intervention group
Intervention type: OTHER
Intervention: Survivor Survey (1): Pre-Visit Baseline
Description: Survivors will participate in a baseline survey regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.
Study NCT02362750 — intervention group
Intervention type: OTHER
Intervention: Survivor Survey (2): Post-Visit
Description: Survivors will participate in a survey within one week after their survivorship visit regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.
Study NCT02362750 — intervention group
Intervention type: OTHER
Intervention: Survivor Survey (3): 3 Month Post-Visit
Description: Survivors will participate in a survey three months after their survivorship visit regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.
Study NCT02362750 — intervention group
Intervention type: OTHER
Intervention: Survivor Survey (4): 6 Month Post-Visit
Description: Survivors will participate in a survey six months after their survivorship visit regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.
Study NCT02362750 — intervention group
Intervention type: OTHER
Intervention: Clinician Survey
Description: Survivorship program clinicians will complete a survey for each survivor who enrolls in the study indicating services provided through the survivorship visit.